The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.
In Dapa-CKD, Farxiga-treated patients without diabetes did numerically better than those with diabetes.
A similar benefit suggests a class effect with the SGLT2s in heart failure, leaving Lilly and Boehringer playing catch-up to Astra.
Positive phase III data in hand, Myokardia heads to the FDA.